Core Insights - Danish drugmaker Novo Nordisk has entered into a licensing agreement with Omeros, which could be valued at up to $2.1 billion for an experimental drug targeting rare blood and kidney disorders [1] Group 1 - The licensing deal signifies a strategic collaboration between Novo Nordisk and Omeros, highlighting the growing interest in treatments for rare diseases [1] - The potential value of the deal, reaching $2.1 billion, indicates significant investment and confidence in the drug's development [1] - The agreement reflects a trend in the pharmaceutical industry towards partnerships to enhance research and development capabilities for niche markets [1]